Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component: Amyloid: Vol 24, No sup1

303

Views

CrossRef citations to date

Altmetric

"Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component." Amyloid, 24(sup1), pp. 5–6

Declaration of interest

MB Pepys is the inventor on patents for CPHPC and CPHPC plus anti-SAP antibody. He founded and owns shares in Pentraxin Therapeutics Ltd, the UCL spinout company that owns these patents and has licenced them to GSK for development.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component

Information for

Open access

Opportunities

Help and information

Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature